Bright Minds Biosciences (TSE:DRUG) has released an update.
Bright Minds Biosciences has announced promising preclinical results for its compound BMB-201, which showed similar pain relief efficacy to morphine without the associated dependency risks. This development is a significant step in providing non-opioid alternatives for neuropathic pain management, with plans to advance into clinical trials.
For further insights into TSE:DRUG stock, check out TipRanks’ Stock Analysis page.
